Novartis's Myfortic granted Australian orphan status
This article was originally published in Scrip
Executive Summary
Novartis's immunosuppressant Myfortic (mycophenolic acid sodium 180mg/360mg) has been granted orphan status by the Australian Therapeutics Goods Administration (TGA) for the induction and maintenance treatment of lupus nephritis – which causes inflammation of the kidney. It received the designation on January 11th.